Your CDx Partner from Translational Research to Global Commercialization

NGS for Pharma

Accelerate access to treatment

Our mission is to advance precision medicine through democratizing NGS globally to enable testing locally, closer to cancer patients.

 

 

Why is Oncomine the partner of choice to pharma?

why-oncomine-icons-ngs

Most innovative NGS technology to deliver fast, automated NGS results from
small samples.

 

why-oncomine-icons-partner

Unparalleled track record and capability of partnering with pharma companies on companion diagnostics from development through regulatory approval, to bring new therapies
to patients.

 

why-oncomine-icons-globe

The only globally distributed NGS CDx solution, commercially available and reimbursed by government and private payors in US, EU, Asia, and Middle East, accelerating patient access to new therapy through local testing.

Ion Torrent NGS Technology

Our technology solves the challenges of routine biomarker testing in clinical oncology. 

  • Shorter turnaround times provide clinicians with timely results for more appropriately informed treatment decisions​
  • Automated workflows reduce labor time and operational costs​
  • Low sample input requirements enables more samples to be tested successfully so more patients can get actionable results

 

oncomine-cd-ngs-comparison-table

Enlarge Image

Oncomine NGS CDx Solutions

Oncomine Dx Target Test was first approved in 2017 and and is still the only commercially distributable multiple biomarker CDx test based on NGS, which can be implemented in new laboratories around the world. Oncomine Dx Express Test is currently under development for future regulatory submissions.

 

  Oncomine Dx Target Test* (Approved) Oncomine Dx Express Test† (In Development)
Sample Type FFPE FFPE, plasma
Number of Genes 46 (EU & Japan), 23 (US and Korea) 46
Alteration Types Mutations (single nucleotide variants, multi-nucleotide variants, insertions, and deletions)​ Mutations, copy number variants, fusions​
Instrument PGM Dx Genexus Dx - In development
Workflow Manual Automated
Turnaround Time (Days)

4

1
Reimbursement Status Reimbursed in most countries launched In Development

Oncomine Dx Target Test CDx Indications

Global Approvals and Commercialization

Oncomine Dx Target Test, is approved and reimbursed by government and commercial insurers in over 15 countries, covering more than 550 million lives globally.

CDx-coverage-icons-1

9
CDx Approved

ALK​
BRAF​
EGFR mutations & deletions​
EGFR insertions​
HER2 (ERBB2) activating mutations
IDH1​
RET​ fusions
RET mutations
ROS1

CDx-coverage-icons-2

12
Pharma Partners

AstraZeneca​
Blueprint Medicines​
Chugai Pharmaceuticals​
Daiichi Sankyo​
Hengrui Therapeutics​
Janssen Oncology​
Lilly Oncology​
Novartis​
Pfizer​
Servier Pharmaceuticals​
Spectrum Pharmaceuticals​
Takeda Pharmaceuticals

CDx-coverage-icons-3

17
Countries

Austria​
Belgium​
Denmark​
Finland​
France​
Germany​
Italy​
Israel​
Japan​
Korea
Netherlands​
Poland​
Saudi​
Spain​
Switzerland​
United Kingdom​
United States

CDx-coverage-icons-4

14
Therapies on Label

afatinib​
alectinib ​
amivantamab-vmjw​
crizotinib​
dabrafenib​ with trametinib ​
entrectinib ​
erlatinib​
fam-trastuzumab deruxtecan-nxki
gefitinib​
ivosidenib​
mobocertinib​
osmeritinib​
pralsetinib​
selpercatinib​

Have questions? Request a CDx consultation.

 

request-contact-cta

ODxTT only available in specific countries. Contact us to learn more.

*For In Vitro Diagnostic Use.
†For investigational use only. The performance characteristics of this product have not been established.

Are you a healthcare professional?

あなたは医療関係者ですか?



We've detected your location to be Japan.